Clinical trial · Observational
Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection (POSTCA)
Dynamic Monitoring of Circulating Tumor DNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection: A Prospective, Multicenter, Clinical Study (POSTCA)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, multicenter, observational, single-blinded controlled study. Dynamic monitoring of patients with resectable colorectal cancer was performed using the previously established colorectal tumor-specific plasma ctDNA methylation markers (Multigene methylation detection). Dynamic monitoring of plasma ctDNA methylation before and after treatment and at regular follow-up in patients with colorectal cancer after radical resection of tumor, to explore the predictive effect of postoperative plasma ctDNA methylation on postoperative recurrence and whether dynamic monitoring of postoperative ctDNA methylation could be earlier than imaging examination to indicate tumor recurrence.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor DNA | Colorectal Neoplasm | PROBABILISTIC | 0.70 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Methylation | — | UNRESOLVED | — |
| Surveillance | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multigene methylation detection | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Colorectal cancer
- description
- Patients diagnosed with resectable colorectal cancer
- interventionNames
- Diagnostic Test: Multigene methylation detection
Primary outcomes (2)
- measure
- Disease Free Survival (DFS)
- timeFrame
- 2-year DFS
- description
- The primary endpoint for this study is Disease Free Survival (DFS), which will be assessed using RECIST version 1.1.
- measure
- ctDNA methylation markers versus CT/MRI
- timeFrame
- 2 years
- description
- ctDNA methylation predictors of outcome will be compared to CT/MRI
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female ≥ 18 years of age on the day of signing informed consent. * Patients must have histologically confirmed colorectal cancer. * Patients need to receive surgical resection. * Patients must have a performance status of ≤1 on the ECOG Performance Scale. * Life expectancy of more than 5 years. * Written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study. Exclusion Criteria: * Patients received adjuvant treatment prior to the surgical resection. * Patients received blood transfusion two weeks before or during the surgical resection. * Patients with unresected advanced colorectal adenoma. * Patients who are positive for Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C. * Patients who are pregnant. * Patients who are alcoholic or drug abusers. * Patients with a history or current evidence of any condition or abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the Investigator.
References
Publications (0)
Data not yet available